Search

Your search keyword '"Matthew C. Hiemenz"' showing total 2 results
Start Over Author "Matthew C. Hiemenz" Publisher wiley
2 results on '"Matthew C. Hiemenz"'

1. <scp>POU2AF3</scp> ‐rearranged sarcomas: A novel tumor defined by fusions of <scp>EWSR1</scp> or <scp>FUS</scp> to a gene formerly designated <scp>COLCA2</scp>

Author

Matthew C. Hiemenz, Jaspreet Kaur, Zheng Kuang, Richard S. P. Huang, Lukas Harries, Dana Metzger, Kelsie Schiavone, Sherri Z. Millis, Douglas I. Lin, Mirna Lechpammer, Brennan Decker, Douglas A. Mata, Abhinav Reddy, Matthew Parke, Eun Y. Lee, Xiaoyan Cui, O. Hans Iwenofu, Darya Buehler, Les Henderson, Erin M. Baldwin, Sosipatros A. Boikos, Shakti H. Ramkissoon, and Steven C. Smith

Subjects
Cancer Research, Genetics
Published
2023

2. Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia

Author

Jennifer Han, Rebecca Gardner, Michael A. Pulsipher, Matthew C. Hiemenz, Maurice R.G. O'Gorman, Matthew J. Oberley, Gordana Raca, Deepa Bhojwani, Alan S. Wayne, Paul S. Gaynon, and Jianling Ji

Subjects
Male, 0301 basic medicine, Myeloid, Oncogene Proteins, Fusion, Population, Immunotherapy, Adoptive, Article, 03 medical and health sciences, Fatal Outcome, 0302 clinical medicine, Immunophenotyping, T-Lymphocyte Subsets, hemic and lymphatic diseases, Basic Helix-Loop-Helix Transcription Factors, Humans, Medicine, Cell Lineage, Myeloid Cells, education, Salvage Therapy, education.field_of_study, Receptors, Chimeric Antigen, biology, business.industry, Hematopoietic Stem Cell Transplantation, Infant, Myeloid leukemia, Hematology, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, Combined Modality Therapy, Chimeric antigen receptor, Leukemia, Myeloid, Acute, Leukemia, 030104 developmental biology, medicine.anatomical_structure, KMT2A, Oncology, 030220 oncology & carcinogenesis, Pediatrics, Perinatology and Child Health, Trans-Activators, Cancer research, biology.protein, Chimeric Antigen Receptor T-Cell Therapy, Cord Blood Stem Cell Transplantation, business
Abstract

A pediatric patient diagnosed initially with B-lymphoblastic leukemia (B-ALL) relapsed with lineage switch to acute myeloid leukemia (AML) after chimeric antigen receptor T-cell (CAR-T) therapy and hematopoietic stem cell transplant. A TCF3-ZNF384 fusion was identified at diagnosis, persisted through B-ALL relapse, and was also present in the AML relapse cell population. ZNF384-rearrangements define a molecular subtype of B-ALL characterized by a pro-B-cell immunophenotype; furthermore, ZNF384-rearrangements are prevalent in mixed-phenotype acute leukemias. Lineage switch following CAR-T therapy has been described in patients with KMT2A (mixed lineage leukemia) rearrangements, but not previously in any patient with ZNF384 fusion.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results